1.5 mg tirzepatide 5mg Tirz 5 mg – Gila

Proper motility helps prevent stagnation of food and bacteria in the small intestine, reducing the risk of bacterial overgrowth

Study 1 (NCT 00123253) This study re-randomized 207 HIV-infected patients with lipodystrophy who completed a 2 mg dose of EGRIFTA (1 mg/vial formulation) treatment in the Main Phase to receive either EGRIFTA (N=154) or placebo (N=50) for an additional 26-week duration (3:1 randomization ratio)

Practical handling: leave the pen out only during injection prep, then return it to the fridge

It acts as an antioxidant by directly scavenging free radicals or serving as a cofactor for antioxidant enzymes 6

IV or highdose uses for lightening are not wellstudied for safety

Trudeau LE, El Mestikawy S